4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001209191-18-052162
EVP, R&D & Chief Scientific Of sold 31,500 shares at an average $40.17 ($1,265,330)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-09-24 | Sale | −14,069 | $39.74 | $559,102 | 317,286 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-09-24 | Sale | −3,931 | $40.53 | $159,323 | 313,355 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-09-25 | Sale | −10,000 | $40.26 | $402,600 | 303,355 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-09-25 | Sale | −3,500 | $41.23 | $144,305 | 299,855 | D |
| Open-market sales · 31,500 sh · avg $40.17 · $1,265,330 | |||||||
Loading xslF345X03/doc4.xml…